The road from drug discovery to treatment can take years, but for the FOP community, every step forward counts. In 2025, several promising medications continue to advance through clinical trials. These drugs, aimed at slowing or halting heterotopic ossification, are being developed and tested with active input from the global FOP community.
Saracatinib, now in its second phase of clinical trials, is receiving global attention. Designed to block unwanted bone formation by targeting the ACVR1 pathway, the drug has already shown potential in early studies. Researchers remain cautiously optimistic, noting fewer flare-ups in trial participants.
Another exciting candidate, INCB000928, also continues to progress. Its selective targeting of the ACVR1 mutation makes it one of the most precise therapies under development. The hope is to develop not just symptom relief, but mutation-specific treatments.
Meanwhile, research into gene therapy is building momentum. Scientists are working on long-term approaches to modify or correct the genetic pathways involved in FOP. Though still in the early stages, this line of research could lead to lasting change.
Additionally, researchers are focusing on flare-up prediction tools and more sensitive imaging technologies. These tools will allow earlier interventions and better quality of life for individuals living with FOP.
These developments are only possible because of families who participate in research, the dedication of clinicians, and the coordination of groups like IFOPA. The FOP treatment pipeline may still be in progress, but it’s moving forward—with the community’s strength behind it.
To learn more, visit: https://foptrust.org/
For international resources, visit: https://www.ifopa.org/
